How are XENE strangle max profit and max loss calculated?

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the XENE strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 46.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$302.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.

What is the breakeven for a XENE strangle?

The breakeven for the XENE strangle priced on this page is roughly $54.48 and $65.53 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current XENE market-implied 1-standard-deviation expected move is approximately 13.27%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.

How does current XENE implied volatility affect this strangle?

XENE ATM IV is at 46.30% with IV rank near 6.90%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.

XENE Strangle Strategy

XENE (Xenon Pharmaceuticals Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and advancing innovative treatments for individuals living with neurological disorders. The company operates primarily from its headquarters in Burnaby, Canada. Its robust clinical pipeline showcases several promising candidates: XEN496, an activator of Kv7 potassium channels, is currently in Phase III clinical trials for KCNQ2 developmental and epileptic encephalopathy. Another Kv7 potassium channel activator, XEN1101, is progressing through Phase II trials, targeting epilepsy and a range of other neurological conditions. The portfolio also includes NBI-921352, a selective inhibitor of the Nav1.6 sodium channel, which is undergoing Phase II clinical evaluation for SCN8A developmental and epileptic encephalopathy, alongside investigations for adult focal epilepsy and other potential indications. Furthermore, XEN007, a central nervous system-acting calcium channel modulator, is also in Phase II development.

XENE (Xenon Pharmaceuticals Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $4.72B, a beta of 0.63 versus the broader market, a 52-week range of 30-63.95, average daily share volume of 1.3M, a public-listing history dating back to 2014, approximately 316 full-time employees. These structural characteristics shape how XENE stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.

A beta of 0.63 indicates XENE has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.

What is a strangle on XENE?

A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.

Current XENE snapshot

As of June 30, 2026, spot at $60.28, ATM IV 46.30%, IV rank 6.90%, expected move 13.27%. The strangle on XENE below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 17-day expiry.

Why this strangle structure on XENE specifically: XENE IV at 46.30% is on the cheap side of its 1-year range, which favors premium-buying structures like a XENE strangle, with a market-implied 1-standard-deviation move of approximately 13.27% (roughly $8.00 on the underlying). The 17-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated XENE expiries trade a higher absolute premium for lower per-day decay. Position sizing on XENE should anchor to the underlying notional of $60.28 per share and to the trader's directional view on XENE stock.

XENE strangle setup

The XENE strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With XENE near $60.28, the first option leg uses a $62.50 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed XENE chain at a 17-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 XENE shares for the stock leg in covered calls and collars).

Action	Type	Strike / Basis	Premium (est)
Buy 1	Call	$62.50	$1.58
Buy 1	Put	$57.50	$1.45

XENE strangle risk and reward

Net Premium / Debit: -$302.50
Max Profit (per contract): Unbounded
Max Loss (per contract): -$302.50
Breakeven(s): $54.48, $65.53
Risk / Reward Ratio: Unbounded

Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.

XENE strangle payoff curve

Modeled P&L at expiration across a range of underlying prices for the strangle on XENE. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.

P&L at expiration across the modeled underlying-price range. Green shading marks profitable regions, red shading marks loss regions. Dotted purple verticals mark breakevens; the solid dark vertical marks current spot.

Underlying Price	% From Spot	P&L at Expiration
$0.01	-100.0%	+$5,446.50
$13.34	-77.9%	+$4,113.79
$26.66	-55.8%	+$2,781.07
$39.99	-33.7%	+$1,448.36
$53.32	-11.5%	+$115.65
$66.65	+10.6%	+$112.07
$79.97	+32.7%	+$1,444.78
$93.30	+54.8%	+$2,777.49
$106.63	+76.9%	+$4,110.21
$119.95	+99.0%	+$5,442.92

When traders use strangle on XENE

Strangles on XENE are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the XENE chain.

XENE thesis for this strangle

The market-implied 1-standard-deviation range for XENE extends from approximately $52.28 on the downside to $68.28 on the upside. A XENE long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current XENE IV rank near 6.90% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on XENE at 46.30%. As a Healthcare name, XENE options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to XENE-specific events.

XENE strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. XENE positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move XENE alongside the broader basket even when XENE-specific fundamentals are unchanged. Always rebuild the position from current XENE chain quotes before placing a trade.

Frequently asked questions

What is a strangle on XENE?: A strangle on XENE is the strangle strategy applied to XENE (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With XENE stock trading near $60.28, the strikes shown on this page are snapped to the nearest listed XENE chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
How are XENE strangle max profit and max loss calculated?: Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the XENE strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 46.30%), the computed maximum profit is unbounded per contract and the computed maximum loss is -$302.50 per contract. Live intraday quotes will differ as the chain moves through the trading session.
What is the breakeven for a XENE strangle?: The breakeven for the XENE strangle priced on this page is roughly $54.48 and $65.53 at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current XENE market-implied 1-standard-deviation expected move is approximately 13.27%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
When should you consider a strangle on XENE?: Strangles on XENE are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the XENE chain.
How does current XENE implied volatility affect this strangle?: XENE ATM IV is at 46.30% with IV rank near 6.90%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.